LA-31

Lactoferrin is a multifunctional iron-binding glycoprotein found in milk, saliva, tears, and mucosal secretions. Its proteolytic breakdown generates a range of bioactive peptide fragments — collectively termed lactoferricins and lactoferrampin — with potent antimicrobial, immunomodulatory, and cytoprotective properties. LA-31 is a synthetic 31-amino acid peptide derived from the bioactive N-terminal and loop domains of lactoferrin, engineered to retain and amplify these activities through structural optimisation.

The peptide encompasses the cationic amphipathic region responsible for lactoferrin's membrane interaction and its ability to activate innate immune signalling pathways. Unlike the native protein (which requires proteolytic processing to release active fragments in vivo), LA-31 is available in pre-processed, optimised form with enhanced resistance to enzymatic degradation and improved bioavailability.

Emerging research interest in LA-31 extends beyond its established antimicrobial properties to include roles in autophagy activation, SIRT1-mediated cellular stress responses, and gut microbiome modulation — placing it at the intersection of antimicrobial peptide research and longevity biology. These broader effects are supported primarily by preclinical data and mechanistic studies, with limited human trials available.

// MEMBRANE DISRUPTION & DIRECT ANTIMICROBIAL ACTIVITY

LA-31 carries a net positive charge at physiological pH, enabling electrostatic attraction to the negatively charged membranes of bacteria, fungi, and certain enveloped viruses. It adopts an amphipathic helical conformation upon membrane contact, inserting into the lipid bilayer and forming pores or causing membrane depolarisation. This mechanism is effective against a broad range of pathogens including MRSA, E. coli, Candida, and H. pylori — with activity enhanced at mucosal surfaces where lactoferrin-derived peptides naturally operate.

// INNATE IMMUNE ACTIVATION & IMMUNOMODULATION

LA-31 engages pattern recognition receptors including TLR4 and TLR2, activating NF-κB-mediated innate immune signalling in macrophages and dendritic cells. It promotes pro-inflammatory cytokine release (TNF-α, IL-6, IL-12) at low concentrations for pathogen clearance, while at higher concentrations modulating the response to prevent excessive inflammation (LPS-induced cytokine storm suppression). This dual immunomodulatory profile mirrors that of other host-defence peptides.

// AUTOPHAGY ACTIVATION & CELLULAR CLEAN-UP

Preclinical evidence suggests LA-31 activates autophagy via AMPK/mTORC1 pathway modulation — increasing the autophagic flux that clears damaged proteins, dysfunctional mitochondria, and intracellular pathogens. Enhanced autophagy is a conserved longevity mechanism: it is activated by caloric restriction, fasting, and other healthspan-extending interventions. LA-31's autophagy-inducing property may underlie its emerging interest in cellular senescence and aging research.

// GUT BARRIER & MICROBIOME MODULATION

Lactoferrin-derived peptides reinforce tight junction integrity in intestinal epithelium, reducing permeability (\"leaky gut\"). LA-31 has shown protective effects against LPS-induced intestinal barrier disruption in cell culture models. Simultaneously, it modulates gut microbiome composition — inhibiting pathogenic species (Clostridium difficile, E. coli, H. pylori) while showing prebiotic-like support for Lactobacillus and Bifidobacterium species. This combination of barrier protection and microbiome modulation is relevant to both immune health and metabolic disease.

Lactoferrin-derived peptide research background: The bioactive properties of lactoferrin fragments have been extensively studied since the 1990s. Lactoferricin B (bovine) and lactoferricin H (human) established the N-terminal loop region as a key pharmacophore. LA-31 extends this research with an optimised synthetic sequence combining elements of multiple active lactoferrin domains.

Preclinical antimicrobial data: LA-31 shows minimum inhibitory concentrations (MICs) in the low µM range against common pathogens. Activity is preserved against biofilm-forming strains and antibiotic-resistant organisms (MRSA, VRE) in vitro.

Longevity and autophagy angle: Connection between lactoferrin-derived peptides and SIRT1/autophagy pathways is supported by mechanistic studies showing upregulation of LC3-II (autophagy marker) in treated cell lines. This represents an emerging research direction with limited but growing preclinical support.

Human data: Lactoferrin itself (the parent protein) has been studied in multiple human trials for gut health, iron supplementation, and immune support. LA-31 as an isolated synthetic peptide lacks dedicated human clinical trials as of 2025. Safety extrapolation from the parent protein is supportive but not directly transferable.